Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Supernus Pharmaceuticals, Inc. (SUPN) had Normalized Income after Taxes of $-58.37M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$219.06M |
|
$-58.37M |
|
$33.67M |
|
$185.39M |
|
$277.02M |
|
$-57.96M |
|
$0.32M |
|
$-57.65M |
|
$-57.65M |
|
$-58.37M |
|
$-58.37M |
|
$-58.37M |
|
|
Normalized Income after Taxes |
$-58.37M |
$-57.96M |
|
$-32.56M |
|
58.07M |
|
58.07M |
|
$-1.01 |
|
$-1.01 |
|
| Balance Sheet Financials | |
$723.50M |
|
$10.20M |
|
$704.61M |
|
$1.43B |
|
$347.38M |
|
-- |
|
$49.51M |
|
$396.88M |
|
$1.03B |
|
$442.34M |
|
$1.03B |
|
58.16M |
|
| Cash Flow Statement Financials | |
$61.71M |
|
$-12.12M |
|
$1.92M |
|
$129.90M |
|
$181.40M |
|
$51.51M |
|
$17.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
84.63% |
|
-26.46% |
|
-26.46% |
|
-- |
|
-26.32% |
|
-26.65% |
|
$61.15M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.40 |
|
1.03 |
|
86.96 |
|
-5.66% |
|
-13.20% |
|
-4.09% |
|
-5.66% |
|
$17.73 |
|
$1.05 |
|
$1.06 |
|